title: Two cases of chronic active Epstein-Barr virus infection in which EBV-specific cytotoxic T lymphocyte was induced after allogeneic bone marrow transplantation.
abstract: CAEBV is a high mortality and morbidity disease with life-threatening complications. Nevertheless, the treatment regimens for CAEBV have not yet been established. Although some reports have described CAEBV therapy involving treatments such as antiviral drugs, immunomodulatory agents, and immunochemotherapy, none of these treatments have been demonstrated to be effective. The only treatment reported to be effective is allogeneic SCT. However, the complications of SCT are severe, so treatment results have been poor. Recently, immunotherapy has been devised, but this is still in the developmental stage. In this report, two cases of CAEBV in which allogeneic SCT was performed soon after diagnosis are reported. In both cases, a high EBV genome titer in the peripheral blood was detected at onset. After SCT, the EBV genome titer decreased as CTL activity gradually increased. This fact suggested that not only high-dose chemotherapy as a preconditioning treatment of SCT but also increased CTL activity which could eliminate virus-infected cells might be effective, although additional cases should be studied in order to establish effective treatments.
authors.affiliation: Department of Pediatrics, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan. miyamu@md.okayama-u.ac.jp
authors.forename: Takako
authors.initials: T
authors.lastname: Miyamura
authors.forename: Kousuke
authors.initials: K
authors.lastname: Chayama
authors.forename: Tomoaki
authors.initials: T
authors.lastname: Wada
authors.forename: Kazunari
authors.initials: K
authors.lastname: Yamaguchi
authors.forename: Nobuko
authors.initials: N
authors.lastname: Yamashita
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Ishida
authors.forename: Kana
authors.initials: K
authors.lastname: Washio
authors.forename: Naoto
authors.initials: N
authors.lastname: Morishita
authors.forename: Akira
authors.initials: A
authors.lastname: Manki
authors.forename: Megumi
authors.initials: M
authors.lastname: Oda
authors.forename: Tsuneo
authors.initials: T
authors.lastname: Morishima
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D000998:Antiviral Agents / Q000494:pharmacology; D016026:Bone Marrow Transplantation / Q000379:methods*; D002648:Child; D002675:Child, Preschool; D020031:Epstein-Barr Virus Infections / Q000097:blood* / Q000175:diagnosis*; D005260:Female; D016679:Genome, Viral; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology; D016219:Immunotherapy, Adoptive / Q000379:methods; D008297:Male; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology* / Q000378:metabolism*; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D000998:Antiviral Agents; D007155:Immunologic Factors